Financing secures path to first NDA submission for buntanetap

6-Month symptomatic data readout anticipated Q1 2027

Alzheimer's disease Phase 3 trial 75% enrolled

Parkinson's disease open-label study 28% enrolled

MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds. Combined with existing cash on hand as well as a recent $1.5 million investment from the Board of Directors Chair, Michael Hoffman, the financing extends Annovis' cash runway through Q2 2027, fully funding the Company's operations through a key symptomatic data readout of its Phase 3 AD trial and the anticipated submission of a New Drug Application (NDA) for buntanetap to the U.S. Food and Drug Administration (FDA).

"This financing is a decisive step forward for Annovis and for patients waiting for a novel Alzheimer's treatment," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "We now have the resources to reach our first major regulatory milestone: the ...